Molecular Monitoring of BCR-ABL Transcripts in Patients With Chronic Myelogenous Leukemia: Is High Sensitivity of Clinical Value?

Posted by rob on March 8, 2010 under Uncategorized | Comments are off for this article

Abstract  Monitoring of disease response during treatment with tyrosine kinase inhibitors of patients with chronic myelogenous leukemia
dramatically changed after the introduction of real-time PCR, which allows quantification of BCR-ABL transcript levels with
high sensitivity and precision. However, its role in patients who have achieved complete cytogenetic response is not entirely
clear; incorrect interpretation of results could lead to unnecessary changes from an effective treatment. This review discusses
the current evidence regarding the benefits, uncertainties, and potential drawbacks of molecular monitoring in patients with
chronic myelogenous leukemia in chronic phase.

Content Type Journal ArticleDOI 10.1007/s11899-010-0046-xAuthors
Maxim Norkin, Wayne State U…
More